Novartis unveiled a promising pipeline of novel vaccines, highlighting vaccine candidates that address significant unmet needs for prevention of fatal diseases such as meningococcal infections and other hospital and community acquired infections. Several vaccine candidates from the Novartis Vaccines research and development portfolio have the potential of being first of its kind.
"Our emerging late and early stage pipeline underscores our commitment to prevention as a means to improve health and address public health challenges," said Dr Joerg Reinhardt, CEO of Novartis Vaccines and Diagnostics. "We are focusing on diseases such as meningococcal meningitis where current vaccines do not protect against all strains that cause this potentially fatal condition which affects up to 500,000 people a year".
The whole story can be read here.
No comments:
Post a Comment